Anti-HMBS Rabbit Monoclonal Antibody for WB, ELISA - P08397

Core Product Specifications and Parameters

Biological Background: HMBS Function and Localization

• HMBS (porphobilinogen deaminase) is a central enzyme in the heme biosynthetic pathway, catalyzing the sequential polymerization of four porphobilinogen molecules to form hydroxymethylbilane (preuroporphyrinogen). Related references: PMID:18004775, PMID:18936296, PMID:19138865
• The enzyme uses a dipyrromethane cofactor that is covalently attached and acts as a primer for tetrapyrrole assembly; the cofactor is regenerated after product release. Related references: PMID:18936296
• HMBS localizes to the cytoplasm (cytosol).
• It is ubiquitously expressed, with an alternatively spliced erythroid‑specific isoform found in erythroid cells.
• Post‑translational modifications include acetylation and phosphorylation (UniProt keywords).
• Genetic variants in HMBS are associated with acute intermittent porphyria, a disorder of heme biosynthesis (UniProt keyword: Disease variant).
• The protein also features a known 3D structure and has been identified in numerous proteomics screens.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 250–350 near the C‑terminus of human HMBS; this region may influence epitope accessibility in native vs. denatured conditions.
• For western blot (WB), consider using whole‑cell lysates from human, mouse, or rat tissues/cell lines, as the antibody cross‑reacts with all three species. Validate detection in the relevant sample system.
• For ELISA, coat with recombinant HMBS or the immunizing peptide; titrate the antibody to determine the optimal working concentration.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio supports IVD manufacturers and research labs with integrated access to raw materials, technical services, and consultative guidance for assay development. This HMBS antibody is well‑suited for studying heme biosynthesis and porphyria‑related research. Through CamelBio’s sourcing network, clients can also obtain validated antibody pairs, optimized monoclonal/polyclonal reagents, ancillary bulk materials, and rare‑target raw materials to streamline their diagnostic workflows.